Holen Sie sich die Stockscreener-App
0.683
2.57%
-0.018
Handel nachbörslich:
.70
0.017
+2.49%
Schlusskurs vom Vortag:
$0.701
Offen:
$0.7499
24-Stunden-Volumen:
139.38K
Relative Volume:
0.88
Marktkapitalisierung:
$4.36M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.27M
KGV:
-0.0319
EPS:
-21.4132
Netto-Cashflow:
$-9.40M
1W Leistung:
-5.10%
1M Leistung:
-3.48%
6M Leistung:
-48.65%
1J Leistung:
-65.67%
1-Tages-Spanne:
$0.6464
$0.7499
1-Wochen-Bereich:
$0.6464
$0.80
52-Wochen-Spanne:
$0.5739
$5.00
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Firmenname
Dermata Therapeutics Inc
Sektor
Branche
Telefon
(858)-223-0882
Adresse
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Vergleichen Sie DRMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
0.683 | 4.59M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Dermata Therapeutics Inc Aktie (DRMA) Neueste Nachrichten
Dermata Therapeutics shareholders approve reverse stock split and key proposals By Investing.com - Investing.com South Africa
Dermata Therapeutics shareholders approve reverse stock split and key proposals - Investing.com
Dermata Therapeutics Holds Annual Stockholders Meeting - TipRanks
What makes Dermata Therapeutics Inc. stock price move sharplyPro Trader Stock Focus - Newser
How Dermata Therapeutics Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
What makes Dermata Therapeutics Inc. Equity Warrant stock price move sharplyFree Low-Risk Investment Plans - Newser
Why Dermata Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
How Dermata Therapeutics Inc. Equity Warrant stock performs during market volatilitySecure Growth Trading Plan - Newser
Why Dermata Therapeutics Inc. Equity Warrant stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
Dermata Therapeutics (DRMA) Stock Price, News & Analysis - MarketBeat
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis - ACCESS Newswire
Breakthrough: First-Ever Topical Botulinum Toxin for Hyperhidrosis Receives Australian Patent - Stock Titan
Dermata Therapeutics (NASDAQ:DRMA) Trading Up 4.7% – What’s Next? - Defense World
Dermata Therapeutics receives extension from Nasdaq panel to meet minimum bid price - Investing.com
Dermata Faces Nasdaq Delisting Risk, Plans Stock Split - TipRanks
CIA(cia protocol) Tokenomics ExplainedFree Membership Group - Newser
Primary Axillary Hyperhidrosis Pipeline 2025: Groundbreaking - openPR.com
Dermata stock hits 52-week low at $0.69 amid market challenges - Investing.com India
Dermata stock hits 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Down 57.0% in May - Defense World
Dermata Therapeutics (NASDAQ:DRMA) Stock Price Down 2% – Time to Sell? - Defense World
Maxim Group Lowers Dermata Therapeutics (NASDAQ:DRMA) Price Target to $3.00 - Defense World
Dermata gears up for phase 3 trial of XYNGARI By Investing.com - Investing.com Nigeria
Maxim Group cuts Dermata Therapeutics target to $3 By Investing.com - Investing.com Nigeria
Dermata gears up for phase 3 trial of XYNGARI - Investing.com
Dermata Therapeutics Begins Manufacturing for STAR-2 Trial - TipRanks
Dermata Therapeutics IncPotential NDA Filing For Xyngari In H1 2028SEC Filing - marketscreener.com
Maxim Group cuts Dermata Therapeutics target to $3 - Investing.com
Dermata Therapeutics (DRMA) Price Target Cut Amid Capital Raise - GuruFocus
Dermata Faces Nasdaq Delisting Risk Over Bid Price - TipRanks
Dermata (DRMA) Achieves Positive Phase 3 Trial Results for Acne Treatment | DRMA Stock News - GuruFocus
DRMA: Substantial Cash Increase Enhances Financial Stability | DRMA Stock News - GuruFocus
Dermata Reports Positive Phase 3 Trial Results - TipRanks
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - ACCESS Newswire
Dermata Therapeutics, Inc. SEC 10-Q Report - TradingView
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - ACCESS Newswire
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - ACCESS Newswire
Finanzdaten der Dermata Therapeutics Inc-Aktie (DRMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):